Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
The primary objective of this trial is to examine the value of prophylactic versus therapeutic breast radiotherapy in Casodex monotherapy induced gynaecomastia and/or breast pain. Patients will receive either prophylactic radiotherapy to the breast at a dose of 12Gy (as two fractions of 6 Gy in consecutives days), or will not receive any radiotherapy prior to commencing CASODEX 150mg monotherapy.
Prostate Cancer
DRUG: Casodex 150mg|PROCEDURE: Radiotherapy|PROCEDURE: Haematology
To examine the value of prophylactic versus therapeutic breast radiotherapy in Casodex monotherapy induced gynaecomastia and/or breast pain
To examine the tolerability of radiotherapy to male breast|To examine the tolerability of Casodex 150mg in localized and locally advanced prostate cancer patients|To examine the efficacy of Casodex 150mg in prostate cancer patients
The primary objective of this trial is to examine the value of prophylactic versus therapeutic breast radiotherapy in Casodex monotherapy induced gynaecomastia and/or breast pain. Patients will receive either prophylactic radiotherapy to the breast at a dose of 12Gy (as two fractions of 6 Gy in consecutives days), or will not receive any radiotherapy prior to commencing CASODEX 150mg monotherapy.